NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/21/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization953.72 mln
Float59.24 mln
Earnings Date11/10/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
39.30
Transformational upside
Relative Strength
10
/ 100
Significantly lagging
Debt / Equity
0.01
Debt-free
ROE
-50.08
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Olema Pharmaceuticals is a clinical-stage company dedicated to developing cancer treatments specifically for women. Its lead drug, palazestrant, works by blocking and breaking down estrogen receptors, and is currently being tested in a major Phase 3 trial for a common and difficult-to-treat form of breast cancer. The company is also running earlier-stage trials combining palazestrant with other targeted therapies, as well as testing a separate drug called OP-3136 in patients with breast and other solid tumors. Founded in 2006 and based in San Francisco, Olema is working to build a pipeline of meaningful treatments for women facing cancer.
